Evidence map›Paper›PMID 42135999›Full record

ArticlePharmacology research & perspectives2026

Activation of TREK-1 and TREK-2 Two-Pore Domain Potassium Channels by the K

E L Veale, P M Matthews, A M Rush, E B Stevens, A Mathie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

E L VealeMedway School of Pharmacy, University of Kent and University of Greenwich, Chatham Maritime, UK.ORCID https://orcid.org/0000-0002-6778-9929
P M MatthewsMetrion Biosciences, Cambridge, UK.ORCID https://orcid.org/0000-0002-9098-5952
A M RushMetrion Biosciences, Cambridge, UK.ORCID https://orcid.org/0000-0001-5422-6142
E B StevensMetrion Biosciences, Cambridge, UK.ORCID https://orcid.org/0000-0001-8308-7938
A MathieMedway School of Pharmacy, University of Kent and University of Greenwich, Chatham Maritime, UK.ORCID https://orcid.org/0000-0001-6094-2890

Funding

Royal Society IF\R1\251048
6 · The paper itself

Abstract

NS5806 is a diaryl-urea small molecule developed for the treatment of pain and neurological disorders. A potent activator of K

Indexed as

Phenylurea CompoundsPotassium Channels, Tandem Pore DomainShal Potassium ChannelsAnimalsHEK293 CellsHumansMembrane PotentialsMiceNeuronsTetrahydronaphthalenesTetrazolesTrigeminal GanglionTwo-Pore Channels(5,6,7,8-tetrahydronaphthalen-1-yl)-(2-(1H-tetrazol-5-yl)phenyl)aminePhenylurea Compoundspotassium channel protein TREK-1Potassium Channels, Tandem Pore DomainShal Potassium ChannelsTetrahydronaphthalenesTetrazolesTwo-Pore ChannelsKV4negatively charged activatorsNS5806TREKtrigeminal neuronstwo‐pore domain potassium channel

Identifiers

PMID42135999
PMCPMC13176460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.